Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J RIESE

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Nature Metabolism|July 23, 2021
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a studyMarja K Puurunen, Jerry Vockley, Shawn L Searle, et al.
Nature Metabolism|August 16, 2022
Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a studyMarja K Puurunen, Jerry Vockley, Shawn L Searle, et al.
Pharmacological Reviews|January 6, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and OncoproteinLauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, et al.
Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.
Plos One|December 30, 2020
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeuticsRichard L Cullum, Lauren M Lucas, Jared I Senfeld, et al.
Cancer Discovery|November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerLawrence Fong, Andrew Hotson, John D Powderly, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Nature Metabolism|July 23, 2021
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a studyMarja K Puurunen, Jerry Vockley, Shawn L Searle, et al.
Nature Metabolism|August 16, 2022
Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a studyMarja K Puurunen, Jerry Vockley, Shawn L Searle, et al.
Pharmacological Reviews|January 6, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and OncoproteinLauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, et al.
Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.
Plos One|December 30, 2020
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeuticsRichard L Cullum, Lauren M Lucas, Jared I Senfeld, et al.
Cancer Discovery|November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerLawrence Fong, Andrew Hotson, John D Powderly, et al.
Pageof 17